A 501(c)(3) organization that fosters philanthropic support for Civica’s work to manufacture and distribute affordable medications, with an initial commitment to support efforts to bring affordable insulin to all Americans.
Civica Foundation centers its giving on one purpose: supporting Civica’s work to manufacture and distribute affordable medications, with an initial commitment to bring affordable insulin to Americans. The foundation operates as a 501(c)(3) public charity and uses philanthropy to back efforts tied to critical medicines and supply continuity. Its active Insulin Initiative Fundraising program is built around biosimilar insulins, including glargine already funded and aspart and lispro in development, with a goal of making insulin available at recommended prices of no more than $30 per vial or $55 per 5-pen pack. Recent grants show the same operational focus in practice. In 2023, Civica Foundation gave $7,552,514 to Civica Inc in Lehi, Utah for alleviating supply shortages, followed by a $6,182,577 grant in 2024 to the same recipient for the same purpose. That pattern points to a funder built around large, targeted support for essential medicines rather than a broad portfolio of unrelated causes. The foundation’s work sits at the intersection of health, pharmaceuticals, insulin access, manufacturing, and supply-chain resilience.
Civica Foundation’s grantmaking is organized around essential medicines and the systems that keep them available. In pharmaceutical manufacturing, it supported Civica Inc with a $7,552,514 grant in 2023 for alleviating supply shortages, tying funding directly to production continuity. The foundation’s insulin work is especially specific. Its Insulin Initiative Fundraising program supports development and launch of Civica biosimilar insulins, including glargine, with aspart and lispro in development, and it frames affordability in terms of recommended prices no higher than $30 per vial or $55 per 5-pen pack. Its stated focus areas also include health, insulin access, drug shortages, and manufacturing. That combination places the foundation squarely in funding for supply-chain and access problems affecting essential consumable items and critical goods.
The reported grant-size distribution is very concentrated at the high end: p25 is $6,525,061, median is $6,867,546, and p75 is $7,210,030. The recent grants show two large awards, one in 2023 and one in 2024, both to the same recipient and both for the same purpose. Civica Foundation is a public charity, not a DAF or a fund that makes program-related investments. It also accepts unsolicited gifts through its Insulin Initiative Fundraising campaign, which is framed as philanthropic partnership support for Civica’s insulin work.
$27.9M
$11.5M
$11.7M
$49.5M
Most grants fall between $6.5M and $7.2M, with a median of $6.9M.
25th Percentile
$6.5M
Median
$6.9M
75th Percentile
$7.2M
Sign up for a free Kindora account to access AI-generated insights into this funder's giving patterns, decision-makers, and fit signals.
Get Started FreeFree Kindora accounts unlock side-by-side comparisons with foundations that share this funder's focus areas and giving profile.
Get Started FreeSign up free to see how well your nonprofit fits this funder, get an AI-generated pitch, and unlock similar foundations.
Civica Foundation gives locally and all reported grants in the data went to recipients in Utah. The grant list places both recent awards in Lehi, UT, and the recipient country distribution is entirely U.S.-based. The foundation’s top state by grant count is Utah, which matches the 100% share of grants going to recipients in the HQ state. The geographic pattern is narrow and fully domestic.
It funds Civica’s work to manufacture and distribute affordable medications, with a particular emphasis on insulin access, drug shortages, manufacturing, and supply shortages. Its active Insulin Initiative Fundraising program supports biosimilar insulins and philanthropic backing for that work.
Its grant-size distribution is tightly grouped: p25 is $6,525,061, median is $6,867,546, and p75 is $7,210,030. The two recent grants both fall within that range.
No. The geographic scope is listed as local, and 100% of grants go to recipients in Utah. The recent grant record also shows both awards going to Lehi, UT.
Yes. The Insulin Initiative Fundraising campaign accepts unsolicited gifts and is presented as a philanthropic partnership effort supporting development and launch of Civica biosimilar insulins.
The recent record shows recurring support to the same recipient in consecutive years: $7,552,514 in 2023 and $6,182,577 in 2024, both to Civica Inc for alleviating supply shortages.
2025
Source: IRS Form 990-PF, fiscal year 2025.
Current and upcoming funding from Civica Foundation that your nonprofit may be able to apply for.
Who can apply: Rural and critical access hospitals meeting program criteria, as defined by the Federal Office of Rural Health Policy. The program is a pilot and is being offered in nine states. Participation has no membership fee and no annual commitment.
Track these deadlines, get reminders, and see how well your nonprofit fits — free with a Kindora account.
Create a free accountDeadlines and eligibility are summarized from public sources and may change — always confirm the details on the funder's official application page before applying.
Most recent grants reported to the IRS.
| Recipient | Location | Amount | Year | Purpose |
|---|---|---|---|---|
| CIVICA INC | LEHI, UT | $27,923,957 | 2025 | ALLEVIATE SUPPLY SHORTAGES |
| CIVICA INC | LEHI, UT | $6,182,577 | 2024 | ALLEVIATE SUPPLY SHORTAGES |
| CIVICA INC | LEHI, UT | $7,552,514 | 2023 | ALLEVIATE SUPPLY SHORTAGES |
CIVICA INC
$27,923,957ALLEVIATE SUPPLY SHORTAGES
CIVICA INC
$6,182,577ALLEVIATE SUPPLY SHORTAGES
CIVICA INC
$7,552,514ALLEVIATE SUPPLY SHORTAGES
